Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,441.65 23.97 0.17%
TOPIX 1,168.98 2.43 0.21%
HANG SENG 22,768.80 72.79 0.32%

Medical Aesthetics Veteran Frederick Beddingfield, III, MD, PhD Appointed New Chief Medical Officer of KYTHERA



  Medical Aesthetics Veteran Frederick Beddingfield, III, MD, PhD Appointed
  New Chief Medical Officer of KYTHERA Biopharmaceuticals

Business Wire

LOS ANGELES -- March 12, 2013

KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH), a biotechnology company
focused on the development and commercialization of prescription products in
aesthetic medicine, today announced the appointment of Frederick Beddingfield,
III, MD, PhD as Chief Medical Officer. Dr. Beddingfield is a board-certified
dermatologist who brings exceptional pharmaceutical and medical device
development experience to KYTHERA. He joins the company from Allergan, Inc.,
where he worked in an executive capacity across the entire aesthetics
portfolio including Botox^® Cosmetic, Juvederm^® and Latisse^®. He most
recently held the role of Vice President and Therapeutic Area Head,
Dermatology and Aesthetics. In addition, he has substantial experience across
medical dermatology including acne, rosacea, hair growth and scar prevention.

"Dr. Beddingfield is recognized as one of the leaders in medical aesthetic
innovation and will immediately become an integral member of KYTHERA's
executive team," said Keith Leonard, KYTHERA’s President and CEO. "His depth
and breadth of experience will undoubtedly help further our mission to bring
great science, clinical rigor and real innovation to the growing area of
medical aesthetics."

Dr. Beddingfield will lead all clinical research and development, including
strategy, operations, statistics, data management, medical writing, regulatory
and quality.

"KYTHERA's spirit of innovation and their unequaled commitment to developing
safe and novel aesthetic treatments is what attracted me to the company," said
Dr. Beddingfield. "I look forward to building on the research success of
ATX-101 and the opportunity to advance aesthetic medicine beyond the current
treatment categories."

An innovative physician-scientist, Dr. Beddingfield has experience working on
premier products in the aesthetics industry, including Allergan's Botox
Cosmetic, Juvederm and Latisse, all market-leading aesthetic treatments in
their respective categories. During his tenure at Allergan, Dr. Beddingfield
served in several roles, including Chief Medical Officer, Allergan Medical,
and Global Team Leader of several brands, including Botox Facial Aesthetics,
Botox Hyperhidrosis, Dermal Fillers and Botox Spasticity. Earlier in his
career, he held a full-time faculty position at UCLA David Geffen School of
Medicine, Division of Dermatology, where he continues to maintain an academic
appointment as Assistant Clinical Professor of Medicine. Dr. Beddingfield
earned an MD degree with honors from the University of North Carolina and a
PhD in Policy Analysis from RAND Graduate School of Policy Studies.

Effective March 23, Dr. Beddingfield succeeds Patricia Walker, MD, PhD, who
joined KYTHERA in 2007 as Chief Medical Officer. Prior to joining KYTHERA, Dr.
Beddingfield worked under Dr. Walker’s tutelage for three years at Allergan.

"We are incredibly grateful to Dr. Walker for all of her contributions in
forming the ATX-101 program and helping to build a strong clinical and
regulatory team," said Mr. Leonard. "We are hopeful she will continue to
contribute to KYTHERA's success as a Corporate Advisor."

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of novel
prescription products for the aesthetic medicine market. KYTHERA’s product
candidate, ATX-101, is a potential first-in-class, injectable treatment
currently in Phase III clinical development for the reduction of submental
fat, which commonly presents as an undesirable "double chin." KYTHERA also
maintains an active research interest in hair and fat biology, pigmentation
modulation and facial contouring. Find more information
at http://www.kytherabiopharma.com.

Botox® Cosmetic, Juvederm® and Latisse® are registered trademarks of Allergan,
Inc.

Contact:

KYTHERA Biopharmaceuticals, Inc.
Investor Contact:
Heather Rowe, 818-587-4559
hrowe@kytherabiopharma.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement